Regeneron Pharmaceuticals Inc — AI technical analysis, September 2026
NYSE/NASDAQ · Biotechnology
AI Recommendation
BUY
Technical score 70/100
Last price: $781.49 · 52W range $541.00 – $859.34
Short answer
Should you buy REGN right now? Stockgaide's AI rates REGN as
BUY, with a technical score of
70/100 at a last price of $781.49.
The 50-day average is above the 200-day average, and RSI sits at 35.3.
Wall Street's consensus rating is 2.11/5.
Full AI analysis for REGN
Strategic Conclusion
Recommendation: Buy
Why? Regeneron trades above both its 50-day and 200-day moving averages, keeping the medium-term uptrend intact. The P/E of 18.59 is reasonable for a large-cap biotech, and the analyst consensus is clearly positive with 26 buys and zero sells. Short-term momentum is cooling — RSI at 35.3 and MACD below signal — but this looks like a pullback within an uptrend rather than a reversal. The technical score of 70/100 supports buying on weakness.
Ideal profile: Long-term investor with a 12+ month horizon; short-term traders should wait for RSI to stabilize before entering.
Price range: Entry zone $750–$770 near the SMA50; upside target $859 (52-week high); stop-loss below $733 (SMA200).
Practical action: Buy on a pullback into $750–$770. Add on a close above $800. Reduce or exit if price closes below $733.
1. Recent Price & Momentum
Current price $781.49 is 9.1% below the 52-week high of $859.34 and 44.4% above the 52-week low of $541.00.
The stock is in the upper-middle part of its 52-week range, not near the top or bottom.
Price is above SMA50 ($751.46) and SMA200 ($733.53), so the medium-term trend remains upward.
Short-term scenario: RSI at 35.3 and negative MACD momentum suggest possible consolidation or a dip toward the SMA50 before the next upward move.
2. Valuation (P/E)
P/E TTM of 18.59 is moderate for a large-cap biotech, especially one with Regeneron’s commercial portfolio and pipeline.
The multiple does not appear to be pricing in aggressive future growth, leaving room for upside if execution continues.
Compared to the broader biotech sector, this valuation is not stretched and supports a buy-on-weakness approach.
3. Technical Analysis
SMA50 ($751.46) is above SMA200 ($733.53) — golden-cross territory, confirming a medium-term uptrend.
RSI(14) at 35.3 is neutral and approaching oversold, but not yet at extreme levels.
MACD at 13.00 is below its signal line of 22.29, with a negative histogram of -9.29 — short-term bearish momentum.
Technical score of 70/100 is a BUY, driven by the moving-average structure and positive analyst sentiment, despite mixed momentum.
4. Analyst Consensus
Mean rating is 2.11/5, with 26 buy, 12 hold, and 0 sell — a moderately positive consensus.
This aligns with the technical score’s BUY signal, though the negative MACD suggests near-term caution.
The analyst view supports buying on dips rather than chasing strength at current levels.
Technical signal details
Rule-based read from price and momentum indicators only — the score behind the AI's recommendation above. Technical score: 70/100 (BUY).
50-day moving average is above the 200-day — medium-term uptrend (golden-cross territory).
MACD is below its signal line — bearish momentum.
RSI at 35.27 — neutral momentum.
Wall Street consensus rating of 2.11 — moderately positive.
Stockgaide's AI currently rates REGN as BUY, with a technical score of 70 out of 100 at a last price of $781.49. This is educational content, not investment advice.
Is REGN in an uptrend?
REGN's 50-day moving average (751.46) is above its 200-day moving average (733.53), which points to a medium-term uptrend.
What is REGN's RSI today?
REGN has a 14-day RSI of 35.3, which places it in neutral territory (above 70 is overbought, below 30 is oversold).
What do analysts say about REGN?
Wall Street analysts covering REGN have a consensus rating of 2.11 out of 5 (1 = Strong Buy), meaning they are moderately positive — 26 Buy · 12 Hold · 0 Sell.
Where is REGN trading in its 52-week range?
REGN last traded at $781.49, against a 52-week range of $541.00 to $859.34 — about 76% of the way up that range.
Get the full AI analysis of REGN
Price targets, fundamentals deep-dive and an AI-written report — free, no signup.